The news: Oura is buying AI primary care company Counsel Health for $625 million in a deal expected to close this year. Counsel offers AI-powered medical chat with the option to consult physicians. Counsel serves consumers directly and partners with employers, health systems, and health plans that may cover or subsidize its services.

Earlier this year, Oura partnered with Counsel to let Oura Ring members ask health questions, receive medical advice, and connect with providers through the Oura app.

Why it matters: The acquisition moves Oura from a health wearable company into medical care services. Unlike earlier wearable acquisitions focused on health coaching, this deal brings healthcare services under Oura’s ownership. It follows through on the ambition Oura laid out in its since-postponed US IPO filing to evolve beyond devices into a health intelligence platform. That platform would turn wearable data into AI-driven medical advice and access to healthcare providers.

Oura says it has 6 million members. The company wants to tell them what's happening in their bodies, as tracked by its smart rings, and then have Counsel help them act on it. Counsel's AI combines connected medical records, past interactions, clinical guidelines, and continuous biometric data to generate personalized guidance. Patients can bring in a physician at any time.

The acquisition also reflects wearables’ push into clinical care as more consumers want doctors to weigh in on device data:

• 23% of physicians said patients seek guidance on using wearable data to manage their health at least weekly, per a July 2026 American Medical Association (AMA) survey of clinicians in North America and Europe.
• 21% said patients ask them to review, interpret, or discuss that data at least weekly, per the same AMA survey.

Even so, physicians remain wary of wearables' clinical value, citing accuracy concerns, false positives, liability, and added workload, per the AMA. Just 6% of physicians in the AMA survey said they integrate wearable data into clinical workflows, a barrier Oura could sidestep by bringing medical guidance directly into its platform through Counsel. That gives members a more direct path to interpreting and acting on their wearable data without waiting for their next doctor's appointment.

Implications for consumer health brands: Oura has already postponed one attempt to go public. Owning Counsel Health lets it pitch public markets on being more than just a device company, which could support a higher valuation when it revisits an IPO. Counsel’s existing enterprise partnerships with providers and payers could also extend Oura’s reach beyond its 6 million members.

For the broader wearables market, the deal is a test case. If Oura members get real value from pairing ring data with Counsel's guidance, the results would strengthen the case for wearables as clinical tools, and could push more physicians to fold device data into care plans. A working model that ties health tracking with medical care could also prompt competitors to pursue similar acquisitions or partnerships.